Evotec Expands Sanofi Link With Exclusive Stem Cell Diabetes Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Evotec’s deal with the French drugmaker to develop stem cell-based treatments for diabetes takes on even more importance following the demise of the biotech’s two lead proprietary candidate therapies.